Sign In
Buy MRK
$119.05
-1.73 (-1.43%)
At Close: Jun 12, 2026
Bourgeon Capital Management LLC Purchases 6,321 Shares of Merck & Co., Inc. $MRK
03:47am, Saturday, 03'rd Jan 2026
Bourgeon Capital Management LLC grew its position in shares of Merck and Co., Inc. (NYSE: MRK) by 3.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities an
Top 10 High-Yield Dividend Stocks For January 2026
01:20am, Saturday, 03'rd Jan 2026
My high-yield dividend watchlist aims for quality stocks at attractive valuations, with a long-term CAGR target of 12%. In December 2025, the watchlist gained 0.03%, outperforming VYM and SPY, though
Merck (MRK) Laps the Stock Market: Here's Why
06:51pm, Friday, 02'nd Jan 2026
The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.13% change from its previous close.
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
05:06pm, Friday, 02'nd Jan 2026
The 10 highest paying dividend stocks in the Dow Jones Industrial Average offer yields from 2.5% to 6.8%. A look at the Dogs of the Dow.
Merck & Co., Inc. $MRK Holdings Boosted by First Pacific Financial
08:14am, Friday, 02'nd Jan 2026
First Pacific Financial raised its stake in Merck and Co., Inc. (NYSE: MRK) by 14.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commi
Financial Consulate Inc. Makes New Investment in Merck & Co., Inc. $MRK
06:34am, Friday, 02'nd Jan 2026
Financial Consulate Inc. bought a new position in Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Comm
Econ Financial Services Corp Takes $2.04 Million Position in Merck & Co., Inc. $MRK
05:56am, Friday, 02'nd Jan 2026
Econ Financial Services Corp purchased a new position in Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (
Merck & Co., Inc. $MRK Stock Position Raised by Generali Asset Management SPA SGR
05:14am, Friday, 02'nd Jan 2026
Generali Asset Management SPA SGR increased its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 42.0% during the undefined quarter, according to the company in its most recent disclosure with
Banque Pictet & Cie SA Sells 246,821 Shares of Merck & Co., Inc. $MRK
04:38am, Friday, 02'nd Jan 2026
Banque Pictet and Cie SA reduced its position in shares of Merck and Co., Inc. (NYSE: MRK) by 23.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Secur
Eldred Rock Partners LLC Buys 13,017 Shares of Merck & Co., Inc. $MRK
05:26am, Thursday, 01'st Jan 2026
Eldred Rock Partners LLC boosted its stake in Merck and Co., Inc. (NYSE: MRK) by 12.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 120,880
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
03:11am, Thursday, 01'st Jan 2026
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining tract
Merck: Framework For Success
02:57am, Thursday, 01'st Jan 2026
Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, b
Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
12:03pm, Tuesday, 30'th Dec 2025
Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, b
Why Merck (MRK) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 30'th Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
09:01am, Tuesday, 30'th Dec 2025
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
